ALPN Profile
Alpine Immune Sciences Inc (ALPN) is a clinical-stage immunotherapy company focused on developing treatments for cancer, autoimmune/inflammatory, and other diseases. The company's proprietary platform, called Transmembrane Immunomodulatory Protein (TIP), is designed to enhance immune responses by selectively activating or inhibiting immune cells in a highly targeted manner.
ALPN has a diverse pipeline of TIP-based therapies, including its lead candidate, ALPN-101, which is in clinical development for multiple indications, including autoimmune and inflammatory diseases. ALPN-202, a dual ICOS/CD28 antagonist, is also in development for autoimmune and inflammatory indications, while ALPN-303, a TIP-based cytokine, is in preclinical development for the treatment of cancer.
The company's strategy includes developing partnerships to advance its programs, as well as exploring potential new applications for its TIP platform technology. In 2020, ALPN entered into a collaboration with AbbVie for the development and commercialization of ALPN-101 for the treatment of psoriasis and other autoimmune diseases.
|
